Gyre Therapeutics (GYRE) Return on Invested Capital (2014 - 2026)

Gyre Therapeutics (GYRE) has 7 years of Return on Invested Capital data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Invested Capital changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, up 1.0% from the prior year.
• Return on Invested Capital retreated to 0.0% in Q1 2026 per GYRE's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.0% in Q1 2023 and bottomed at 0.02% in Q1 2022.
• The 5-year median for Return on Invested Capital is 0.0% (2023), against an average of 0.0%.
• Peak annual rise in Return on Invested Capital reached 2 bps in 2023, while the deepest fall reached 2 bps in 2023.
• Tracing GYRE's Return on Invested Capital over 5 years: stood at 0.0% in 2022, then plunged by 1912 bps to 0.02% in 2023, then soared by 63 bps to 0.01% in 2024, then jumped by 110 bps to 0.0% in 2025, then plunged by 258 bps to 0.0% in 2026.
• Per Business Quant, the three latest GYRE Return on Invested Capital figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).

Peer Comparison